Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Wright Reports
|
$449.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
AcelRx Pharmaceuticals Inc Announces $5.6 Million Department of Defense Grant To Develop ARX-04
AcelRx Pharmaceuticals Inc announced that the US Army Medical Research and Material Command (USAMRMC) has awarded AcelRx a $5.6 million grant to support the development of a new product candidate, ARX-04, a proprietary non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain.
Latest Developments for AcelRx Pharmaceuticals Inc
- AcelRx Pharmaceuticals Inc Announces Top-Line Data Demonstrate Primary Endpoint Achieved In Final Pivotal Phase 3 Study Of Sufentanil Nanotab PCA System For Management Of Post-Operative Pain
- AcelRx Pharmaceuticals Inc Announces That Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain
- AcelRx Pharmaceuticals Inc Announces Appointment Of Chairman-Form 8-K
- AcelRx Pharmaceuticals Inc Announces Exercise of Option to Purchase Additional Shares
Latest Key Developments in Biotechnology
- Adherex Technologies Inc Reports Feedback From FDA From End Of Phase 2 Meeting
- Venaxis Inc Announces Pricing Of Offering Of Common Stock And Warrants
- Elan Corporation PLC Rejects Latest Royalty Pharma Approach-WSJ
- Apricus Biosciences Inc Prices $17.1 Million Public Offering Of Common Stock And Warrants
- Share this
- Link this
- Digg this
Follow Reuters